Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind Randomized Placebo-controlled Comparative Multicenter Study to Assess the Safety, Tolerability and Efficacy of XC221 in a Dose of 200mg Per Day in Patients With Uncomplicated Influenza or Other ARVI

NCT03830905 is registered in ClinicalTrials.gov with PHARMENTERPRISES LLC as lead sponsor.

NCT NCT03830905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03830905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind Randomized Placebo-controlled Comparative Multicenter Study to Assess the Safety, Tolerability and Efficacy of XC221 in a Dose of 200mg Per Day in Patients With Uncomplicated Influenza or Other ARVI
Lead sponsor
PHARMENTERPRISES LLC
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2019
Completion date
July 3, 2019
Enrollment
120 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory viral infections, influenza